Vaccine

Survey demonstrates that individuals with COPD seek more options to reduce risks of seasonal respiratory viral infections

-- ENA Respiratory and COPD Foundation survey confirms patients are overwhelmingly positive about taking an immune-modulating nasal spray to reduce…

2 years ago

Veru to Report Fiscal 2023 First Quarter Financial Results on February 9, 2023

MIAMI, FL, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines…

2 years ago

PDS Biotech Announces Participation in the Channelchek Takeaway Series

FLORHAM PARK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a…

2 years ago

AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial

AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial…

2 years ago

Cell BioEngines Enters into an Exclusive Worldwide Agreement to Develop and Commercialize Potent Immune Cell States to Cure Cancer

Mount Sinai’s Dr. Nina Bhardwaj and Cell BioEngines Founder and CEO Dr. Ajay Vishwakarma Mount Sinai’s Dr. Nina Bhardwaj and…

2 years ago

Press Release: NEJM publishes once-weekly efanesoctocog alfa Phase 3 data demonstrating its potential to transform the treatment landscape for people with hemophilia A

 NEJM publishes once-weekly efanesoctocog alfa Phase 3 data demonstrating its potential to transform the treatment landscape for people with hemophilia…

2 years ago

VPM oversees clinical trial and translational project management – Positive Phase I data of client Memo Therapeutics AG

HANNOVER, Germany, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Vakzine Projekt Management GmbH (VPM), a German drug development consultancy and service…

2 years ago

Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate

JUPITER, Fla., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI),…

2 years ago

IO Biotech Announces Appointment of Devin Smith as General Counsel

Mr. Smith joins IO Biotech bringing over two decades of legal and compliance experience in the life science industriesNEW YORK,…

2 years ago